FDA CMC Flexibilities for Cell and Gene Therapy
FDA CMC Flexibilities for Cell and Gene Therapy: What Sponsors Need to Get Right GMP Bridge Content Team 28.08.2026 Biotech In May 2026, FDA issued final guidance on CMC flexibilities for human cellular and gene therapy products being developed toward a Biologics License Application (BLA). The guidance recognises the practical constraints of CGT development, including […]
Inside Biopharma M&A Due Diligence
Inside Biopharma M&A Due Diligence: How GMP Audits Shape Smarter Investment Decisions GMP Bridge Content Team 09.03.2026 Biopharma,Biotech In today’s biopharma, biologics, and cell & gene therapy (CGT) landscape, mergers, acquisitions, and strategic investments move fast — often faster than the time it takes to truly understand a site’s GMP maturity. That’s where biopharma due […]
QMS Simplification
QMS Simplification — The Overlooked Advantage in Biologics Scale-Up GMP Bridge Content Team 05.03.2026 Biotech For many Biologics and ATMP companies, the transition from clinical to commercial supply is the moment of truth. And too often, the bottleneck is not science, manufacturing capacity, or even funding. It is the Quality Management System (QMS) and QMS […]